ALC Alcon Inc.
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. In addition it also develops and commercializes therapies for chronic eye diseases, focusing on encapsulated cell therapy platforms for ocular conditions. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Alcon (SWX: ALC)
›
Alcon (SWX: ALC) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 25,000 employees.
The shares were at 62.28 CHF on 20 November 2026, down 2.3% over 52 weeks. Its 52-week range is 47.80 CHF to 68.34 CHF: the price is 8.9% below the high and 30.3% above the low.
At a market capitalisation of 29.92B CHF, it trades at 57.1 times trailing earnings and 17.3 times forward earnings. The median trailing P/E of its 18 largest Medical Instruments & Supplies peers is 45.0, a premium of 27% for ALC. It pays a dividend yielding 0.44% (it pays out 26% of its earnings), against a median of 1.05% among the dividend payers in that peer group.
Alcon reports return on equity of 4.4%, an operating margin of 12.9% and revenue up 4.7% year over year.
Its debt exceeds its cash by 3.53B USD, a debt-to-equity ratio of 0.24. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 17 analysts cover the stock, with an average rating of Buy; their mean price target of 74.06 CHF is 18.9% above the current price. The next earnings report is expected on 23 February 2027.